The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

I. Shimomura | H. Kaneto | T. Matsuoka | A. Imagawa | H. Yokoyama | Y. Irie | T. Yasuda | H. Watada | Y. Umayahara | S. Shimizu | K. Ryomoto | Tsunehiko Yamamoto | N. Maeda | S. Sumitani | Takehiro Yamamoto | S. Sasaki | D. Kawamori | M. Hajime | M. Narisawa | T. Nakamura | T. Shiraiwa | M. Saito | M. Takahara | N. Katakami | Y. Fujishima | J. Kozawa | M. Otsuki | H. Iwahashi | M. Shimoda | Y. Fujita | A. Tokunaga | Y. Okada | T. Mita | H. Yoshii | T. Osonoi | K. Mukai | K. Ohtoshi | K. Kosugi | Y. Sato | K. Maeda | Y. Takahi | Y. Kiyohara | K. Fukui | S. Kamei | Y. Okada | A. Fukuhara | A. Kurozumi | Yasunori Sato | H. Ninomiya | I. Sato | Y. Okuno | A. Tamazawa | Tadashi Nakamura | S. Uno | T. Yamamoto | Hideki Taki | S. Yoneda | K. Torimoto | N. Kuribayashi | I. Hayashi | M. Tsugawa | Tadashi Nakamura | S. Kawashima | I. M. H. H. K. T. T. T. S. T. S. T. M. K. K. H. H. T. Hayashi Tsugawa Yokoyama Yoshii Komiyama Mita | K. Komiyama | T. Shimizu | T. Kinoshita | K. Maeda | H. Ishida | N. Fujiki | K. Kato | R. Kataoka | M. Ohashi | Y. Hosokawa | T. Katsura | T. Kimura | S. Kobayashi | F. Kubo | N. Maeda | K. Miyashita | S. Nakata | H. Nishizawa | F. Sakamoto | N. Shimo | I. Shimomura | T. Takano | M. Yamaoka | K. Koikawa | F. Kuno | K. Matsushita | K. Tanaka | K. Sugai | Y. Kiyohara | K. Matsushita | M. Saito | S. Sasaki | K. Maeda | K. Kato | T. Kimura | K. Tanaka | T. Yamamoto | S. Kobayashi | H. Taki | T. Nakamura | R. Kataoka | K. Fukui | H. Yokoyama | K. Maeda | Keisuke Kosugi | Satoru Sumitani | T. Nakamura

[1]  D. Simonson,et al.  Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. , 1998, JAMA.

[2]  J. Steiner,et al.  A Systematic Review of the Literature , 2019, HIV/AIDS and Adolescents.

[3]  V. Drapeau,et al.  Impact of Weight Reduction on Eating Behaviors and Quality of Life: Influence of the Obesity Degree , 2009, Obesity Facts.

[4]  L. Delahanty,et al.  Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials , 2018, The Patient - Patient-Centered Outcomes Research.

[5]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[6]  D. Spruijt-Metz,et al.  Occupational Therapy Intervention Improves Glycemic Control and Quality of Life Among Young Adults With Diabetes: the Resilient, Empowered, Active Living with Diabetes (REAL Diabetes) Randomized Controlled Trial , 2018, Diabetes Care.

[7]  S. Takeishi,et al.  Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study. , 2017, Endocrine journal.

[8]  H. Bilo,et al.  Cross-sectional relationship between glycaemic control, hyperglycaemic symptoms and quality of life in type 2 diabetes (ZODIAC-2). , 2005, The Netherlands journal of medicine.

[9]  H. Ishii,et al.  Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study) , 2020, Diabetes Therapy.

[10]  K. Fox,et al.  Association of Self-Reported Weight Change and Quality of Life, and Exercise and Weight Management Behaviors Among Adults with Type 2 Diabetes Mellitus: The SHIELD Study , 2012, Cardiology research and practice.

[11]  Y. Terauchi,et al.  Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study , 2014, Cardiovascular Diabetology.

[12]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  H. Ishii,et al.  Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study) , 2018, Diabetology & Metabolic Syndrome.

[14]  Y. Terauchi,et al.  Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials , 2014, Expert opinion on pharmacotherapy.

[15]  H. Ishii,et al.  Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires. , 2008, Diabetes research and clinical practice.

[16]  T. Fukuzawa,et al.  Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice , 2012, Journal of Pharmacology and Experimental Therapeutics.

[17]  S. Grandy,et al.  Changes in weight loss‐related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin , 2014, Diabetes, obesity & metabolism.

[18]  T. Wadden,et al.  The impact of a primary care-based weight loss intervention on the quality of life , 2013, International Journal of Obesity.

[19]  Roy Taylor,et al.  Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial , 2017, The Lancet.

[20]  S. Bolge,et al.  Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes , 2017, International journal of general medicine.

[21]  F. Camacho,et al.  The Diabetes Medication Satisfaction Tool (DMSAT): A Focus on Treatment Regimens , 2008 .

[22]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[23]  I. Shimomura,et al.  The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis , 2017, Diabetes Therapy.

[24]  H. Ishii.  Development and Psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) Questionnaire , 2012, Journal of medical economics.

[25]  I. Shimomura,et al.  Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study , 2020, Cardiovascular Diabetology.

[26]  K. Munir,et al.  Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes , 2018, Expert opinion on pharmacotherapy.

[27]  M. Krebs,et al.  Assessing the health-related quality of life in type 2 diabetes patients treated with insulin and oral antidiabetic agents , 2019, Wiener klinische Wochenschrift.

[28]  N. Ejskjaer,et al.  The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease , 2021, Diabetes Therapy.

[29]  I. Shimomura,et al.  Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study , 2017, Diabetes Therapy.

[30]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[31]  I. Shimomura,et al.  Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial , 2021, Cardiovascular Diabetology.

[32]  S. Grandy,et al.  Health‐related quality of life (EQ‐5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years , 2014, International journal of clinical practice.

[33]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[34]  F. Yoshikawa,et al.  Efficacy of intermittent empagliflozin supplementation on dietary self‐management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24‐week randomized controlled trial , 2018, Diabetes, obesity & metabolism.